27 completed, 3 terminated, 3 unknown, 2 not yet recruiting. 27 Phase 1, 6 Not applicable, 1 Early Phase 1, 1 Phase 2, 1 Phase 4.
Follow Pharmacokinetic: new trials by email Literature Review of Pharmacokinetic trials Research Report on Pharmacokinetic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human SAD and MAD Study in HV to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-01-01 | 2026-10-16 |
| Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment Olverembatinib 20mg - Pharmacokinetic, Olverembatinib | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 48 | 2025-11-11 | 2025-12-23 |
| Phase 1 Pharmacokinetic Study of Minoxidil SL Tablets Strength A Sublingual Minoxidil, Strength B Sublingual Minoxidil - Pharmacokinetic | Phase 1 | Completed | Samson Clinical Operations Pty Ltd | 12 | 2024-11-06 | 2025-02-17 |
| A Pharmacokinetic Study of Single Oral Doses of Six Different Vitamin C Product Forms TP1, TP2, TP3 - Healthy, Pharmacokinetic | Not applicable | Completed | dsm-firmenich Switzerland AG | 27 | 2024-07-01 | 2025-01-10 |
| Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI Ketamine - Analgesia, Ketamine | Completed | Pontificia Universidad Catolica de Chile | 20 | 2024-04-30 | 2024-08-22 | |
| A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body Regimen 1 (Oral primaquine), Regimen 2 (IV primaquine phosphate), Regimen 3 (IV carboxyprimaquine) - Healthy, Pharmacokinetic | Phase 1 | Withdrawn | University of Oxford | 2024-03-01 | 2024-05-06 | |
| A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects Lanifibranor - Pharmacokinetic | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 24 | 2023-10-31 | 2024-01-02 |
| Clinical Study to Compare the Effect of an Oral Rehydration Solution on the Rate of Absorption of Functional Ingredients Hydration Multiplier + Energy, Hydration Multiplier + Sleep, Energy Comp - Absorption, Pharmacokinetic | Not applicable | Completed | Liquid I.V. | 37 | 2023-10-01 | 2024-07-29 |
| Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD), immediate-release nicotinic acid (SAD), Placebo controlled-ileal-release nicotinic acid (SAD/MAD) - Safety Issues, Pharmacokinetic | Phase 1 | Completed | University Hospital Schleswig-Holstein | 60 | 2022-12-19 | 2024-11-27 |
| Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects Artemether-lumefantrine, Amodiaquine, Artemether-lumefantrine + Amodiaquine - Pharmacokinetic, Healthy | Phase 1 | Terminated | University of Oxford | 8 | 2022-11-01 | 2026-01-12 |
| Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU Intensive Care Unit, Antibiotic Therapy | Not yet recruiting | Poitiers University Hospital | 2500 | 2022-09-01 | 2022-08-04 | |
| F573 Ia Clinical Trial F573, Placebo - Tolerance, Pharmacokinetic | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 100 | 2021-02-08 | 2022-11-08 |
| Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM) controlled-ileocolonic-release nicotinamide (SAD/MAD/MD), Immediate-release nicotinamide (SAD), Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD) - Safety Issues, Pharmacokinetic | Phase 1 | Completed | University Hospital Schleswig-Holstein | 49 | 2020-12-04 | 2022-11-08 |
| Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects INV-101, Placebo - Pharmacokinetic | Phase 1 | Completed | Inversago Pharma Inc. | 40 | 2020-09-08 | 2025-03-30 |
| A Pharmacokinetic Study of PLENVU® in Healthy Subjects PLENVU powder for oral solution - Pharmacokinetic | Phase 1 | Completed | Norgine | 19 | 2020-09-03 | 2023-11-29 |
| Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults Abiraterone acetate tablets - Abiraterone Acetate, Gene Polymorphism | Early Phase 1 | Unknown | Zhongnan Hospital | 81 | 2020-05-05 | 2022-01-03 |
| A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects SHR-1314 - Pharmacokinetic | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 30 | 2020-04-07 | 2020-03-30 |
| A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 Formulation A GS-248, Formulation B GS-248 - Pharmacokinetic | Phase 1 | Completed | Gesynta Pharma AB | 14 | 2020-03-31 | 2021-08-31 |
| Clinical Trial on Pharmacokinetic and Tolerability of AP701 AP701 - Pharmacokinetic, Tolerability | Phase 1 | Completed | CannaXan GmbH | 15 | 2020-01-11 | 2021-03-10 |
| Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections chest tube drainage, antibiotic concentration in pleural fluid, Amoxicillin + clavulanic acid - Pleural Infection, Empyema | Not applicable | Completed | Centre Hospitalier Universitaire, Amiens | 11 | 2019-07-18 | 2025-12-08 |
Showing 20 of 37. Sign in to see all of them.
Acute-On-Chronic Liver Failure (1) · Agnosia (1) · Community-Acquired Pneumonia (1) · Critical Illness (1) · Empyema (1) · Fibrosis (1) · Inflammatory Bowel Diseases (1) · Liver Failure (1) · Liver Failure, Acute (1) · Marijuana Abuse (1) · Motor Activity (1) · Multiple Organ Failure (1) · Prediabetic State (1) · Sepsis (1) · Shock, Septic (1)
Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (3) · Digestive System Diseases (2) · Infections (2) · Inflammation (2) · Behavior (1) · Chemically-Induced Disorders (1) · Community-Acquired Infections (1) · Diabetes Mellitus (1) · Disease Attributes (1) · Endocrine System Diseases (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Glucose Metabolism Disorders (1) · Hepatic Insufficiency (1)
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine (2) · Amodiaquine (2) · Artemether, Lumefantrine Drug Combination (2) · Moxifloxacin (2) · Primaquine (2) · Sagittal Abdominal Diameter (2) · Tapentadol (2) · 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (1) · 5-amino-2-((1-n-propyl-1H-imidazol-4-yl)methyl)pentanoic acid (1) · 8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline (1) · Abiraterone Acetate (1) · Amoxicillin (1) · Amoxicillin-Potassium Clavulanate Combination (1) · Clarithromycin (1) · Glipizide (1)
Grünenthal GmbH (3) · University of Oxford (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Tris Pharma, Inc. (2) · University Hospital Schleswig-Holstein (2) · Ascentage Pharma Group Inc. (1) · AstraZeneca (1) · Bausch Health Americas, Inc. (1) · Beijing Continent Pharmaceutical Co, Ltd. (1) · CannaXan GmbH (1) · Centre Hospitalier Universitaire, Amiens (1) · Chinese Academy of Sciences (1) · Chulalongkorn University (1) · Gesynta Pharma AB (1) · HK inno.N Corporation (1)
China (6) · Germany (6) · Thailand (5) · United States (4) · Belgium (2) · Canada (2) · France (2) · Australia (1) · Chile (1) · South Korea (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Susanna Nikolaus, Prof. Dr. (2) · Borimas Hanboonkunupakarn, Asst. Prof (1) · Da F Zhong, PH.D (1) · Egbert Seidel, MD, PhD (1) · Eva Berger, Dr (1) · Helena Litorp, MD, PhD (1) · Jae-Gook Shin (1) · Liyan Miao, M.D.,Ph.D. (1) · Luis I Cortinez, MD (1) · Philip Evans, MBChB, MRCS (1)
PMID 32318268, PMID 33230714, PMID 36100355, PMID 39546215
2017 (1)